This was the stock's second consecutive day of gains.

Pharmaceutical companies raised the list prices of at least 250 prescriptions heading into 2025 as major changes to the ...

Pharmaceutical companies are raising the price of over 250 brand drugs this year. Nearly all the price increases are under 10 ...

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $56.56 which represents a slight increase of $0.50 or 0.89% from the prior close of $56.06. The stock opened at $56.07 and ...

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report), with a price ...

While the New Year's tradition of drug price hikes has held firm for years, pharma companies have decidedly tamped down on ...

Meanwhile, drugmakers are expected to raise prices on over 250 medications in the new year; rules for hospital price transparency are updated; and more.

Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...

Experts propose potential workarounds for obstacles to wider use of combined clinics and personalized medicine for ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...